| Co-Investigator(Kenkyū-buntansha) |
RIEHM Hansjog Hanover University Department of Medicine・Professor, 医学部, 教授
BUCHNER Thomas Munster University Department of Medicine・Professor, 医学部, 教授
TOMONAGA Masao Nagasaki University Department of Medicine・Professor, 医学部, 教授 (40100854)
FUJIMOTO Takeo Aichi Medical University Department of Medicine・Professor, 医学部, 教授 (10037442)
|
|---|
| Research Abstract |
Federal Republic of Germany (FRG) now leads the world in the field of leukemia therapy. The strategy of curative intensive therapy and the number of patients involved in their nation-wide clinical studies surpass those of U. S. A or other parts of Europe. The rapid rise of quality and quantity of their clinical studies of leukemia has derived from government-supported funds for the war against cancer which started in 1979. Their concept was characterized by the emphases on the role of biostatistics in planning of protocols and the analysis of data, and 5 biostatistc centers were established throughout FRG. Unlike in U. S. A, , FRG government did not support to establish oncology groups, but formed project teams on each cancer. Each project team receives approximately 20 to 50 x 10^6 Yen per year for about 5 to 7 years. For example, in the fields of adult leukemia, there are 3 project teams ; acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia, and they receive in total about 4 to 7 times of funds compared to those of the project team on adult leukemia in Japan which is supported by the Ministry of Health and Welfare and the official members of which are only up to 12 institutions. Through the present investigation, the reason why FRG has emerged as a super power in the field of clinical cancer study has become clear. FRG government has funded the clinical research as well as basic science in the war against cancer. In Japan, the 10-year war against cancer, which started in 1984, has funded almost exclusively basic research such as biotechnology. To establish high-standard clinical cancer study in Japan, more governmental funds should be distributed to clinical studies, at least to establish biostatistic centers which plan and control the clinical studies.
|
